Cite
MLA Citation
M D Berger et al.. “61PDGenetic variations within the HER3 gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab or FOLFIRI/cetuximab: Data from FIRE-3.” Annals of oncology, vol. 29, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100095323761.0x00003b